A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

被引：38
|
作者：
Zeidan, Amer M. [1 ,2 ]
DeAngelo, Daniel J. [3 ]
Palmer, Jeanne M. [4 ]
Seet, Christopher S. [5 ]
Tallman, Martin S. [6 ]
Wei, Xin [7 ]
Li, Ying Fei [8 ]
Hock, Nanette [9 ]
Burgess, Michael R. [9 ]
Hege, Kristen [9 ]
Stock, Wendy [10 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Celgene Corp, Berkeley, NJ USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene Corp, San Francisco, CA USA
[10] Univ Chicago Med, Chicago, IL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-125363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1320
引用
收藏
页数：6
相关论文
共 50 条
  • [31] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [32] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    BLOOD, 2011, 118 (21) : 1550 - 1550
  • [34] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [36] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
    Halpern, Anna B.
    Estey, Elihu H.
    Othus, Megan
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Chen, Tara L.
    Becker, Pamela S.
    Scott, Bart L.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Shadman, Mazyar
    Stirewalt, Derek L.
    Walter, Roland B.
    BLOOD, 2014, 124 (21)
  • [37] EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)
    Taussig, David
    de Leeuw, David C.
    Jongen-Lavrencic, Mojca
    O'Nions, Jenny
    Koko, Thinzar
    Searle, Emma
    Fisher, Geoff
    Brook, Sue
    Arkenau, Hendrik-Tobias
    Yusuf, Ayan Aden
    Tan, Peter
    BLOOD, 2024, 144 : 1500 - 1501
  • [38] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [39] A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Nazha, Aziz
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Faderl, Stefan
    Estrov, Zeev
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [40] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
12345